sgp130 in Chronic Human Liver Disease
Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.
Alcoholic Liver Disease
Chronic Hepatitis C Virus Infection
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Study of IL-6 Transsignaling in Chronic Human Liver Disease|
plasma, liver biopsies, and peripheral blood mononuclear cell culture medium.
|Study Start Date:||January 2005|
|Study Completion Date:||October 2008|
|Primary Completion Date:||January 2007 (Final data collection date for primary outcome measure)|
alcoholic liver disease
alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
chronic HCV hepatitis
chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00770198
|Hopital Erasme - Dpt of Gastroenterology|
|Brussels, Belgium, 1070|
|Principal Investigator:||Arnaud Lemmers, MD||Erasme Hospital, Gastroenterology Dpt|